Your browser doesn't support javascript.
loading
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Zhou, Xiaofei; Vaishampayan, Ulka; Mahalingam, Devalingam; Harvey, R Donald; Chung, Ki Young; Sedarati, Farhad; Dong, Cassie; Faller, Douglas V; Venkatakrishnan, Karthik; Gupta, Neeraj.
Afiliação
  • Zhou X; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. xiaofei.zhou@takeda.com.
  • Vaishampayan U; Karmanos Cancer Institute, Detroit, MI, USA.
  • Mahalingam D; University of Michigan, Ann Arbor, MI, USA.
  • Harvey RD; Northwestern Medical Group, Chicago, IL, USA.
  • Chung KY; Emory University, Atlanta, GA, USA.
  • Sedarati F; Prisma Health Cancer Institute/ITOR, Greenville, SC, USA.
  • Dong C; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Faller DV; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Venkatakrishnan K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
  • Gupta N; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Invest New Drugs ; 40(5): 1042-1050, 2022 Oct.
Article em En | MEDLINE | ID: mdl-35932388
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifampina / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Invest New Drugs Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rifampina / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Invest New Drugs Ano de publicação: 2022 Tipo de documento: Article